No 340B Savings for Transgender Care Act

This bill would stop clinics and hospitals in the 340B drug discount program from using their drug savings to pay for transgender health care. Specifically, it bans using the difference between the 340B discount price and what the provider paid for the drug to fund sex reassignment surgeries or hormone treatments for transgender people.

Key points:

• Who is affected: 340B “covered entities” (like many hospitals and community clinics) and transgender patients seeking surgery or hormone therapy at those sites.
• What changes: These providers could not use their 340B savings to cover costs for those surgeries or hormone treatments. The rule targets only the savings from the drug discount, not all other funds.
• When: If this became law, the restriction would apply once in effect; the text does not give a separate start date.